Tag:
MedImmune
Latest Headlines
Latest Headlines
Brennan's ouster at AstraZeneca sets stage for big changes in R&D
The ongoing restructuring underway at AstraZeneca claimed one more employee today: The chief architect.
AstraZeneca scouts new drug deals to silence a chorus of critics
The instant the news hit that Amylin had rebuffed a $3.5 billion buyout offer from Bristol-Myers Squibb, analysts began to speculate that AstraZeneca might like to step in.
AstraZeneca's FluMist Quadrivalent to hit U.S. market
The FDA has approved AstraZeneca's ( $AZN ) nasal FluMist Quadrivalent flu vaccine for use in people ages 2 to 49. Made at AstraZeneca's MedImmune unit, FluMist Quadrivalent contains two...
AstraZeneca's FluMist Quadrivalent to hit U.S. market
The FDA has approved AstraZeneca's ( $AZN ) nasal FluMist Quadrivalent flu vaccine for use in people ages 2 to 49. Made at AstraZeneca's MedImmune unit, FluMist Quadrivalent contains two...
Icahn biotech whiz Denner jumps ship after 5 turbulent years
Carl Icahn's right hand man in the biotech sphere, Alex Denner, has turned in his walking papers. He has resigned from Icahn Enterprises, according to Bloomberg, after five years of boardroom coups
MedImmune cell-culture plant named facility of the year
A large-scale mammalian cell-culture-based production facility built by MedImmune , a unit of AstraZeneca ( $AZN ), has been named facility of the year by competition sponsors ISPE, INTERPHEX and
Merck, MedImmune deal space
Capacity issues have led to a facility relationship deal between MedImmune and Merck ( $MRK ). The former will provide space in its Frederick, MD, facility for bulk product manufacturing by the latter.
Soured motavizumab deal triggers MedImmune suit against partner Abbott
Eight months after AstraZeneca ( $AZN ) wrote off a star program for motavizumab, along with $445 million, its MedImmune subsidiary in Maryland has fired off a nasty lawsuit against Abbott over their
AZ loses round in Lucentis patent fight
An English judge has dealt a blow to AstraZeneca by overruling the patent rights of MedImmune, its subsidiary, to a screening technique used in drugs like Roche's blockbuster eye treatment Lucentis.
WSJ: Hedge fund's MedImmune profits spur SEC insider probe
The Wall Street Journal reports this morning that the big hedge fund SAC Capital Advisors is being investigated for possible insider trading related to AstraZeneca's $15 billion acquisition of
